First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
<p>Abstract</p> <p>Imatinib, a tyrosine kinase inhibitor (TKI) of BCR-ABL, was the standard first-line therapy for chronic myeloid leukemia (CML) for almost 10 years. Dasatinib and nilotinib, two newer drugs with higher potency than imatinib against BCR-ABL and activity against mos...
Main Authors: | Rafiyath Shamudheen, Wei Guoqing, Liu Delong |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-11-01
|
Series: | Journal of Hematology & Oncology |
Online Access: | http://www.jhoonline.org/content/3/1/47 |
Similar Items
-
Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
by: T Pavey, et al.
Published: (2012-11-01) -
Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
by: Radhakrishnan Ramchandren, et al.
Published: (2009-05-01) -
Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation
by: B. Uz, et al.
Published: (2011-01-01) -
Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation.
by: E Loveman, et al.
Published: (2012-05-01) -
Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
by: Charles Chuah, et al.
Published: (2009-04-01)